Caladrius Biosciences, INC. Stock: price and management transactions · United States · SEC (Form 4)

About Caladrius Biosciences, INC.

Caladrius Biosciences, Inc. (ticker: CLBS) is a United States biopharmaceutical company associated with the NASDAQ market. For French-speaking investors, it should be viewed as a clinical-stage biotech focused on cell therapy and regenerative medicine rather than a mature, cash-generating pharma platform. Historically, the company built its franchise around innovative cellular therapeutics designed to reverse or meaningfully alter severe disease progression, with an emphasis on cardiovascular and other chronic indications. The company’s headquarters were disclosed in SEC and NASDAQ materials as Basking Ridge, New Jersey, placing it within one of the core U.S. biotech clusters. ([nasdaq.com](https://www.nasdaq.com/press-release/caladrius-biosciences-closes-%245.0-million-registered-direct-offering-priced-at-the?utm_source=openai)) In terms of business lines, Caladrius has concentrated on CD34+ cell-based therapeutic candidates and on indications with significant unmet medical need. SEC filings and company disclosures reference programs in coronary microvascular dysfunction (CMD), critical limb ischemia (CLI), Buerger’s disease, type 1 diabetes, and diabetic kidney disease. Examples include XOWNA/CLBS16 for CMD, HONEDRA/CLBS12 for CLI, and CLBS201 for diabetic kidney disease. This gives the company a clearly differentiated scientific profile, but also makes it highly dependent on clinical outcomes, regulatory progress, and access to capital. ([sec.gov](https://www.sec.gov/Archives/edgar/data/320017/000114036122023089/R27.htm?utm_source=openai)) From a competitive standpoint, Caladrius sits in a niche where scientific barriers are high but competition is intense among cell-therapy and regenerative-medicine developers. Its investment case has historically hinged on clinical data quality, the potential for favorable regulatory designations, and the company’s ability to fund long development timelines. NASDAQ press releases over time show repeated equity financings and other capital-raising actions, underscoring the funding-heavy nature of its development model, which is common for small-cap biotech issuers. ([nasdaq.com](https://www.nasdaq.com/press-release/caladrius-biosciences-closes-%245.0-million-registered-direct-offering-priced-at-the?utm_source=openai)) Recent milestones matter for interpretation of current insider filings. The most recent SEC text available in the search results still describes a portfolio centered on XOWNA/CLBS16, HONEDRA/CLBS12, and CLBS201, alongside ongoing clinical work. However, Caladrius also announced a merger agreement with Cend Therapeutics in 2022 to form Lisata Therapeutics, which materially changed the company’s corporate story. As a result, investors analyzing CLBS Form 4 insider transactions should verify the exact legal entity and listing status at the time of the filing, because the historical Caladrius narrative may not fully match the current listed company structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/320017/000032001722000064/a425rochepressrelease20220.htm?utm_source=openai))